348 related articles for article (PubMed ID: 10202049)
1. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine.
Guinn BA; DeBenedette MA; Watts TH; Berinstein NL
J Immunol; 1999 Apr; 162(8):5003-10. PubMed ID: 10202049
[TBL] [Abstract][Full Text] [Related]
2. 4-1BBL enhances anti-tumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors.
Guinn BA; Bertram EM; DeBenedette MA; Berinstein NL; Watts TH
Cell Immunol; 2001 May; 210(1):56-65. PubMed ID: 11485353
[TBL] [Abstract][Full Text] [Related]
3. Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency.
Cayeux S; Richter G; Becker C; Beck C; Aicher A; Pezzutto A; Dörken B; Blankenstein T
Eur J Immunol; 1997 Jul; 27(7):1657-62. PubMed ID: 9247574
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors.
Martin-Fontecha A; Cavallo F; Bellone M; Heltai S; Iezzi G; Tornaghi P; Nabavi N; Forni G; Dellabona P; Casorati G
Eur J Immunol; 1996 Aug; 26(8):1851-9. PubMed ID: 8765031
[TBL] [Abstract][Full Text] [Related]
5. Role of IL-12 and 4-1BB ligand in cytokine production by CD28+ and CD28- T cells.
Chu NR; DeBenedette MA; Stiernholm BJ; Barber BH; Watts TH
J Immunol; 1997 Apr; 158(7):3081-9. PubMed ID: 9120260
[TBL] [Abstract][Full Text] [Related]
6. Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules.
Moro M; Gasparri AM; Pagano S; Bellone M; Tornaghi P; Veglia F; Corti A; Casorati G; Dellabona P
Cancer Res; 1999 Jun; 59(11):2650-6. PubMed ID: 10363988
[TBL] [Abstract][Full Text] [Related]
7. Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus.
DeBenedette MA; Wen T; Bachmann MF; Ohashi PS; Barber BH; Stocking KL; Peschon JJ; Watts TH
J Immunol; 1999 Nov; 163(9):4833-41. PubMed ID: 10528184
[TBL] [Abstract][Full Text] [Related]
8. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.
Li Y; McGowan P; Hellström I; Hellström KE; Chen L
J Immunol; 1994 Jul; 153(1):421-8. PubMed ID: 7515929
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic antitumor response to cervical cancer in mice immunized with U14 vaccines transfected with costimulatory B7 gene.
Tao G; Hu J; Zou H; Lin Q; Liu F; Wu Y; Sun Q
Chin Med J (Engl); 2001 Jun; 114(6):623-7. PubMed ID: 11780440
[TBL] [Abstract][Full Text] [Related]
10. B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro.
Lu ZY; Condomines M; Tarte K; Nadal L; Delteil MC; Rossi JF; Ferrand C; Klein B
Exp Hematol; 2007 Mar; 35(3):443-53. PubMed ID: 17309825
[TBL] [Abstract][Full Text] [Related]
11. B7-2 expression above a threshold elicits anti-tumor immunity as effective as interleukin-12 and prolongs survival in murine B-cell lymphoma.
Pizzoferrato E
Int J Cancer; 2004 May; 110(1):61-9. PubMed ID: 15054869
[TBL] [Abstract][Full Text] [Related]
12. 4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses.
Tan JT; Whitmire JK; Ahmed R; Pearson TC; Larsen CP
J Immunol; 1999 Nov; 163(9):4859-68. PubMed ID: 10528187
[TBL] [Abstract][Full Text] [Related]
13. The capacity of the natural ligands for CD28 to drive IL-4 expression in naïve and antigen-primed CD4+ and CD8+ T cells.
Bian Y; Hiraoka S; Tomura M; Zhou XY; Yashiro-Ohtani Y; Mori Y; Shimizu J; Ono S; Dunussi-Joannopoulos K; Wolf S; Fujiwara H
Int Immunol; 2005 Jan; 17(1):73-83. PubMed ID: 15569772
[TBL] [Abstract][Full Text] [Related]
14. Efficient inhibition of human B-cell lymphoma in SCID mice by synergistic antitumor effect of human 4-1BB ligand/anti-CD20 fusion proteins and anti-CD3/anti-CD20 diabodies.
Liu R; Jiang W; Yang M; Guo H; Zhang Y; Wang J; Zhu H; Shi R; Fan D; Yang C; Zhu Z; Xie Y; Xiong D
J Immunother; 2010 Jun; 33(5):500-9. PubMed ID: 20463597
[TBL] [Abstract][Full Text] [Related]
15. Malignant B lymphocytes from non-Hodgkin's lymphoma induce allogeneic proliferative and cytotoxic T cell responses in primary mixed lymphocyte cultures: an important role of co-stimulatory molecules CD80 (B7-1) and CD86 (B7-2) in stimulation by tumor cells.
Plumas J; Chaperot L; Jacob MC; Molens JP; Giroux C; Sotto JJ; Bensa JC
Eur J Immunol; 1995 Dec; 25(12):3332-41. PubMed ID: 8566020
[TBL] [Abstract][Full Text] [Related]
16. Co-modification of IL-2-TNF alpha fusion gene and B7.1 gene to murine breast tumor cells leads to improved tumor rejection and vaccine effect.
Liu X; Zhang L; Zhang M; Ma Y; Xu X; Cai Y
Chin Med J (Engl); 2000 Feb; 113(2):167-71. PubMed ID: 11775545
[TBL] [Abstract][Full Text] [Related]
17. Costimulation of CD28- T lymphocytes by 4-1BB ligand.
DeBenedette MA; Shahinian A; Mak TW; Watts TH
J Immunol; 1997 Jan; 158(2):551-9. PubMed ID: 8992967
[TBL] [Abstract][Full Text] [Related]
18. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro.
Gajewski TF
J Immunol; 1996 Jan; 156(2):465-72. PubMed ID: 8543795
[TBL] [Abstract][Full Text] [Related]
19. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer.
Xiang J; Chen Y; Moyana T
Cancer Gene Ther; 2000 Jul; 7(7):1023-33. PubMed ID: 10917205
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of antitumor CTL response by GM-CSF involves a B7-dependent mechanism.
Mokyr MB; Kalinichenko TV; Gorelik L
Cell Immunol; 1997 Jun; 178(2):152-61. PubMed ID: 9225006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
